# PROFOUND MEDICAL CORP. (PROF) · Edgar & Edgarette company card

> Profound Medical (PROF) grew revenue 50.7% in FY2025 to $16 million, operating margin -256% against a 1.2% median for surgical & medical instruments & apparatus, equity 85.7% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1628808 · fiscal year ended 2025-12-31 · 3 audited years read · [page](https://www.pops4.com/boards/company/PROF) · [JSON](https://www.pops4.com/boards/company/PROF.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $16M |
| Revenue growth, 1 year | 50.7% |
| Revenue growth per year | 49.5% |
| Operating margin | -256.3% (prior year -309.6%) |
| Net margin | -264.4% |
| Operating cash flow | −$38M |
| Capital spending | $176,000 |
| Free cash flow | −$38M |
| Cash | $60M |
| Long-term debt | $4M |
| Total assets | $77M |
| Total equity | $66M |
| Equity ÷ assets | 85.7% |
| Return on equity | -64.1% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -3.44 (distress zone)
- Piotroski F: 4 of 9 (middling)
- Health Harbor boat: Old boat · three warning signs · operating cash flow was negative; operating loss: a margin of -256.3% in FY2025; revenue is hard to predict: its 80% range is ±28%
- Cash Compass: Fast, cash not yet · growing fast, but little cash arriving so far

## Edgarette's reading

Exposure: revenue $16.1M (FY2025), total debt $4.5M. Experience: revenue up 50.7% on the year, up 49.5% a year over 2 years; operating margin -256.3%, up from -309.6%. Soundness: equity 85.7% of assets, return on equity -64.1%. Credibility: 3 audited years, moderate weight. Range: 80% of past cases like this landed between $17.7M and $31.8M next year (method v3, set from 749 SEC company-years; on a year the method never saw, 83% landed inside). A statistical range, not company guidance. Against peers (60 filers, $50M+ revenue, surgical & medical instruments & apparatus): operating margin -256.3% against a 1.2% median; growth 50.7% against 11.6%.

Range logged 2026-09-20, receipt c5c5a4b4ac568ca5, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 3, latest 2026-09-03 ([filing](https://www.sec.gov/Archives/edgar/data/1628808/000117184326005868/0001171843-26-005868-index.htm))

## Recent filings

- 8-K · filed 2026-11-03 · 1.01 Entry into a Material Definitive Agreement; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1628808/000110465926121980/0001104659-26-121980-index.htm)
- 8-K · filed 2026-10-22 · 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1628808/000117184326006781/0001171843-26-006781-index.htm)
- 8-K · filed 2026-10-14 · 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1628808/000117184326006615/0001171843-26-006615-index.htm)
- 8-K · filed 2026-10-09 · 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1628808/000117184326006559/0001171843-26-006559-index.htm)
- 8-K · filed 2026-10-07 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1628808/000117184326006499/0001171843-26-006499-index.htm)
- 8-K · filed 2026-09-04 · 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1628808/000117184326005884/0001171843-26-005884-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001628808.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1628808

## Cite

POPS4, Edgar & Edgarette: PROFOUND MEDICAL CORP. (PROF) company card, from the company's own SEC filings, accessed 2026-11-04, https://www.pops4.com/boards/company/PROF. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.